of diluted 10% brain homogenates prepared from a scrapie strain 139A (courtesy of R.H. Kimberlin, Edinburgh, UK) infected mouse. All animals were monitored twice weekly for clinical signs of disease development. Mice were sacrifi ced at 125 days post infectionem (dpi) and at the terminal stage of the disease. The terminal stage was reached when the development of scrapie symptoms indicated that the animals would die, if not sacrifi ced, within the next 72 h. One brain hemisphere was formaldehyde-fi xed for morphological evaluation, and the other hemisphere was frozen and used for characterization of misfolded proteinase K-resistant prion protein (PrP Sc ) by Western blot analysis. For the Western blot procedure, 10% brain homogenates from 2 animals per group were subjected to proteinase K-digests as previously described [8] . The subsequent detection of PrP Sc was performed using the anti-PrP antibody 6H4 (Prionics, Switzerland).
Immunohistochemical detection of glial fi brillary acid (GFAP)-expressing astrocytes was performed according to previously published procedures [9] using polyclonal anti-GFAP antiserum (Dako, Denmark).
In order to detect differences in the degree of spongiform lesions, PrP Sc deposition, and astrocytosis, a quantitative scoring system was applied. The entire brain section in each specimen was examined and the degree of lesion was graded from 0 to 3+ according to the severity of damage. Examined areas were the cortex, hippocampus, brain stem, cerebellum, and the olfactory bulb. Differences between Fyn -/-mice and the wild-type controls were evaluated by independent scoring of all tissue samples by three investigators without prior knowledge of the group to which the mice belonged.
The comparison of the Fyn -/-mice with the wild-type controls concerning the gliosis, the accumulation of misfolded proteinase K-resistant prion protein (PrP Sc ) and the scrapie-associated vacuolization of the neuropil revealed no signifi cant differences for the examined parameters.
The expression of activated, GFAP-expressing astrocytes ( fi g. 1 ) was unchanged in the Fyn -/-mice compared to the wild-type controls. Thus, the Fyn signaling cascade is not involved in the development of the astrogliosis in our model of chronic neurodegeneration. However, a recent report by Chun et al. [10] described the overexpression of Fyn kinase by reactive astrocytes due to neural trauma, which points towards a possible participation of astrocytic Fyn activation in acute neurodegeneration.
The ablation of the Fyn gene did not affect the extent of PrP res deposition when analyzed by Western blotting ( fi g. 2 ) indicating that the Fyn kinase is not relevant for the conversion of the normal cellular prion protein into the disease-associated isoform PrP Sc . Furthermore, no difference was seen concerning vacuolization of the neuropil, which is a hallmark of prion disease-associated neurodegeneration [11] ( fi g. 1 ).
Finally, Fyn -/-mice succumbed to the disease on average at 175 8 9 (dpi), whereas the wild-type controls died at 184 8 9 dpi ( table 1 ). The duration of the symptomatic phase and the clinical symptoms in the Fyn -/-mice were identical to the controls. The survival time differences of on average 9 days are borderline signifi cant (p ! 0.05) and may suggest that intact Fyn signalling is to some extent neuroprotective. Interestingly, PrP expression has been suggested to be associated with neuroprotective anti-apoptotic functions [12] . Thus, PrP-triggered Fyn activation may be involved in signalling pathways, which promote neuronal survival. Conversely, cross-linking of cellular PrP by monoclonal antibodies, which was reported to induce Fyn kinase activation in vitro [13] , triggers neuronal apoptosis in vivo. Hence, Fyn could theoretically be also involved in signalling cascades leading to neuronal loss. However, it was recently shown that for example PrP-triggered activation of extracellular regulated kinases 1/2 (ERK 1/2) is not necessarily Fyn-dependent but can be controlled by NADPH oxidase in certain cell types [5] indicating that PrP-mediated signalling is complex and may vary for different tissues.
Taken 
